KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...

Sebetralstat is a novel oral plasma kallikrein inhibitor aimed at treating HAE attacks in adults and adolescents aged 12 and older. The drug has also been submitted for regulatory review by the U ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary ...

SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The company has also submitted a new drug application ...

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...

In other recent news, KalVista Pharmaceuticals has been making significant strides in the development of sebetralstat, a potential game-changer in the treatment of hereditary angioedema (HAE). The ...

"Sebetralstat is poised to be the first and only oral on-demand treatment for HAE, with the potential to become the foundational treatment for this disease," said Ben Palleiko, Chief Executive ...

Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief– –Pooled data analysis showed adolescents treated with ...